Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells

The New York Times reports telomere shortening a major contributor to aging

BALTIMORE, March 22, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and Danielle R. Baker, Ph.D., of Frontage Laboratories will present a scientific poster presentation at the Global Longevity Federation Conference in Las Vegas on March 26th at 2 pm EDT. The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.

The basic theory behind Telomir’s research is the concept that elongating telomeres, which are repetitive DNA sequences at the end of chromosomes that protect chromosomes from becoming frayed or tangled, could result in stimulating stem cell renewal and thus the treatment of age-related conditions like osteoarthritis.

This presentation builds on the data that was presented at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024 in February. The poster, titled “Telomir-1 Induces Telomere Extensions in Primary Human Cell Strains,” will be presented by Dr. Baker and will include new data that further demonstrates that total telomere length was augmented following various Telomir-1 treatments, supporting the hypothesis that Telomir-1 elongates telomeres.

Telomir believes this research is important and timely as society looks to deal with the challenges associated with aging. As reported in a March 20, 2024, article in The New York Times, titled “Why Do We Age?,” “as we age, telomere shortening becomes a problem, particularly in stem cells, which the body uses to replenish skin, blood and other tissue.” Telomir is working to develop and commercialize Telomir-1 which it believes will elongate telomeres and potentially reversing age-related conditions.